The U.S. Centers for Medicare & Medicaid Services agreed to provide Medicare beneficiaries with reimbursement for CGMs that are approved for informing diabetes treatment decisions. This landmark decision means more people than ever can reap the benefits of state-of-the-art diabetes technology.